Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tysabri Safety Study To Commence Following Lift Of Clinical Hold

Executive Summary

Biogen Idec/Elan's monotherapy safety extension study of its multiple sclerosis therapy Tysabri will help shape FDA's risk management demands for the biologic, assuming it is re-approved

You may also be interested in...

Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says

Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call

Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts